STOCK TITAN

Elicio Therapeutics (ELTX) awards 60,833 stock options to its CFO

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Elicio Therapeutics, Inc. reported that Chief Strategy and Financial Officer Preetam Shah received a grant of stock options covering 60,833 shares of common stock at an exercise price of $3.20 per share. The options expire on July 16, 2036 and vest 50% on July 16, 2027 and 50% on July 16, 2028, subject to his continued service.

Positive

  • None.

Negative

  • None.
Insider Shah Preetam
Role See Remarks
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 60,833 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 60,833 shares (Direct)
Footnotes (1)
  1. [object Object]
Stock options granted 60,833 shares Stock option grant to Chief Strategy and Financial Officer on 2026-07-16
Exercise price $3.20 per share Conversion or exercise price of the granted stock options
Options held after grant 60,833 options Total stock options reported following the transaction
Expiration date July 16, 2036 Expiration date of the stock options granted to Preetam Shah
First vesting tranche 50% of options Vests and becomes exercisable on July 16, 2027, first anniversary of grant
Second vesting tranche 50% of options Vests and becomes exercisable on July 16, 2028, second anniversary of grant
Grant transaction price $0.00 per option Award of options reported with no cash price paid per option at grant
Stock Option (Right to Buy) financial
"Security title listed as "Stock Option (Right to Buy)""
exercise price financial
"Conversion or exercise price of $3.2000 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The stock option vests and becomes exercisable as to 50% of the options"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"The option carries an expiration date of 2036-07-16"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
continued service financial
"Subject to the Reporting Person's continued service to the Issuer"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Elicio Therapeutics (ELTX) disclose in this Form 4 for Preetam Shah?

Elicio Therapeutics disclosed that Chief Strategy and Financial Officer Preetam Shah received a stock option grant for 60,833 shares of common stock with a $3.20 exercise price, expiring on July 16, 2036, subject to a two-year vesting schedule.

How many ELTX shares are covered by the new stock option grant to Preetam Shah?

The new stock option grant to Preetam Shah covers 60,833 shares of Elicio Therapeutics common stock. All 60,833 options are reported as held following the transaction and are subject to future vesting conditions before becoming fully exercisable.

What is the exercise price of the stock options granted to the ELTX CFO?

The stock options granted to Elicio Therapeutics’ Chief Strategy and Financial Officer carry an exercise price of $3.20 per share. This price applies to all 60,833 underlying common shares once the options have vested and are exercisable.

What is the vesting schedule for the 60,833 ELTX stock options granted to Preetam Shah?

The option vests in two equal installments: 50% on July 16, 2027 and 50% on July 16, 2028. Vesting is subject to Preetam Shah’s continued service to Elicio Therapeutics through each respective vesting date.

When do the newly granted ELTX stock options to Preetam Shah expire?

The stock options granted to Preetam Shah have an expiration date of July 16, 2036. Any unexercised portion of the 60,833 options will cease to be exercisable after that date, assuming they have vested under the stated schedule.

Was any cash paid per share in this ELTX Form 4 option grant transaction?

The Form 4 shows a transaction price of $0.00 per option for the grant, indicating it was an award of stock options rather than a market purchase, with a separate $3.20 exercise price applicable when options are exercised in the future.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shah Preetam

(Last)(First)(Middle)
C/O ELICIO THERAPEUTICS, INC.
451 D STREET, 5TH FLOOR, SUITE 501

(Street)
BOSTON MASSACHUSETTS 02210

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Elicio Therapeutics, Inc. [ ELTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$3.207/16/2026A60,833 (1)07/16/2036Common Stock60,833$060,833D
Explanation of Responses:
1. The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Remarks:
Chief Strategy and Financial Officer
/s/ Preetam Shah07/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)